查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495998

全球安全针市场 - 2024年至2029年预测

Global Safety Needles Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年安全针市值为429,215,000美元，预计2029年将达到1,002,348,000美元，复合年增长率为12.88%。

安全针是一种先进的需求，具有内建的安全机制，可以避免针刺伤患者。预计在预测期内推动市场成长的关键原因是疾病的增加和增加疫苗接种以避免慢性病。随着生活方式变得更加复杂，慢性病盛行率增加，诊断、治疗和免疫接种的支出大幅增加，安全针市场不断扩大。

此外，为了更好地预防有害病原体进入体内的潜在感染，对一次性安全针头的需求也为产业扩张提供了新的机会。此外，老年人口的增加以及对改善身体结构的安全针的需求也推动了市场的成长。政府对医疗保健领域的大力投资预计也将带来稳定成长。

从地区来看，调查分为北美、南美、欧洲、中东/非洲和亚太地区。亚太地区和北美地区预计将占据主要市场占有率。亚太地区正在成为医疗保健中心。与他们的祖国相比，美国人和欧洲人发现该地区的治疗具有成本效益且便宜。透过在亚太地区接受治疗，普通美国人可以节省高达 90% 的医疗保健费用。而且，该地区医疗基础设施和设施的增加预计将进一步扩大医疗旅游市场，并带来安全针的显着成长。

在欧洲地区，由于老年人口比例较高以及慢性病，特别是心血管疾病的显着增加，对用于诊断、治疗和药物摄入的安全注射器的需求预计将增加。

市场驱动因素：

  • 医疗保健支出的增加和疾病发生率的上升预计将扩大市场。

推动安全注射器市场成长的关键原因之一是医疗保健支出和疾病案例的增加。随着生活方式变得更加复杂，心血管疾病的病例正在迅速增加。诊断、治疗和药物摄取量显着增加，增加了安全针的适用性。根据世界卫生组织（WHO）的资料，2019年有17.9名患者死于心血管疾病，占当年死亡人数的32%。 646万65岁以下的人死于CVD。

慢性病的增加显着增加了医疗保健成本，以改善医疗保健。根据世界银行资料，全球人均卫生支出从2015年的999.104美元增加到2018年的1,111.082美元。医疗成本和治疗费用的上涨预计将推动安全针头市场的激增。

此外，国际组织也正在采取倡议，透过提高意识提升计划、药物和治疗来减轻慢性病的负担。世卫组织的目标是在 2010 年至 2025 年间将全球血压问题的盛行率降低 25%。世卫组织宣布，到 2025 年，该计划的 50% 受益者将接受持续的药物治疗和其他治疗，以预防与 CVD 相关的死亡。预防和治疗的良好前景预计将扩大市场机会。

市场限制因素：

  • 注射器和针头废弃物的增加会造成环境威胁，进而阻碍市场的发展。

安全针产业面临的一个主要问题是针处置。安全注射器主要是一次性注射器，其处置不当会造成注射器和针头的污染。随着针头和注射器使用的增加，世界各地的注射器污染急剧增加。 2021 年 3 月，旧金山共收集了超过 13,000 个注射器和废弃物，比 10 年前增加了 10 倍。此外，针头处理不当会增加传播爱滋病毒和肝炎等疾病的可能性。蓬勃发展的注射器市场预计将进一步增加污染，这会导致环境恶化，因此引起人们的担忧。

主要发展

  • 2023 年 1 月 - MTD 集团的 DropSafeTM SicuraTM 被动安全针头获得 FDA 批准，用于肌肉内和皮下注射疫苗和药物。该针头旨在消除针刺伤害，并提供完全安全的注射体验。针头受到透明护罩的保护，注射后会自动锁定，无需医疗保健专业人员 (HCP) 逐步启动。 HCP 安全一直是 MTD Group 的首要任务，DropSafeTM SicuraTM 将在美国各地的药房连锁店和其他医疗机构提供。
  • 2023 年 1 月 - Milestone Scientific 与瑞典和 Martina 合作，在西班牙、葡萄牙和法国销售 STA 单牙麻醉系统(R)。该协议赋予瑞典和玛蒂娜 STA 在这些市场的独家经销权，并取代其目前在义大利的经销商。 STA 系统采用数位化、电脑控制的精确剂量，可提供无痛注射、缩短等待时间、减少併发症和减少患者取消注射。
  • 2022 年 11 月 - Neogen Corporation 为生产农民推出了一款新型双感测针，增强了 Ideal® D3™ 感测针的有效性。正在申请专利的 D3X 针是 Neogen Corporation 的金属合金针，其侧壁经过加固，可提高负载强度并降低弯曲或断裂的风险。此外，还使用了高度可见的红色提取环，以防止针头陷入动物的皮肤中。
  • 2022 年 3 月 - NuGen Medical Devices 与 Harrington Consultants Limited 和 Al Mufid Pharmaceuticals 签署了一份为期五年的无针注射器 InsuJet(TM) 经销协议。该合约将为科威特支付至少 200 万加元，但须经科威特卫生局核准。科威特成年人糖尿病盛行率为24.9%，位居世界第三。 InsuJet(TM) 是加拿大卫生署核准的第一个自行注射无针注射系统，为数百万患有糖尿病和其他慢性病的患者提供安全且经济高效的药物输送。

主要市场区隔

按类型

  • 主动安全针
  • 被动安全针

依给药途径

  • 皮下的
  • 静脉
  • 其他的

按最终用户

  • 医院/诊所
  • 门诊治疗中心
  • 诊断中心
  • 其他的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 其他的
  • 中东/非洲
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行概述

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球安全针市场：按类型

  • 介绍
  • 主动安全针
  • 被动安全针

第六章全球安全针市场：依给药途径分类

  • 介绍
  • 皮下的
  • 静脉
  • 其他的

第七章全球安全针市场：依最终用户分类

  • 介绍
  • 医院和诊所
  • 门诊治疗中心
  • 诊断中心
  • 其他的

第八章全球安全针市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • BD
  • Cardinal Health
  • B. Braun Melsungen Ag
  • Medline Industries, Inc.
  • Johnson & Johnson Services, Inc.
  • Nipro Medical Corporation
  • Smith's Group Plc
  • Metier Medical Limited
  • Olympus Corporation
简介目录
Product Code: KSI061611907

The global safety needles market was valued at US$429.215 million in 2022 and is forecasted to reach US$1,002.348 million by 2029, growing at a CAGR of 12.88%.

Safety needles are advanced needs having the feature of an inbuilt safety mechanism that can avoid needle-linked injuries to the patients. The prime reason that is expected to drive the market growth during the forecasted period is the growing advent of diseases and rising vaccination in an attempt to avoid chronic diseases. With rising complexities in lifestyle and the growing prevalence of chronic diseases, expenditure on diagnosis, treatments, and vaccinations has surged significantly, which has increased the market for safe needles.

Furthermore, the demand for single-use safety needles for better prevention against potential infection of unwanted pathogens entering the body has provided a new opportunity for the industry's expansion. Moreover, an increase in the geriatric population and demand for safe needles for better body suitability also drive the market growth. Robust investment by the government in the healthcare sector is also projected to provide stable growth.

Geographically, the global safety needles are divided into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific regions for the study. The Asia Pacific and North American regions are expected to hold a significant market share. The Asia Pacific region has been emerging as a medical hub. Compared to their countries, Americans and the European population find medical treatment in this region more cost-effective and cheaper. An average American can save up to 90% of the expenditure on healthcare if the patient gets treatment from the Asia Pacific region. Furthermore, rising healthcare infrastructure and facilities in the region will further expand the medical tourism market and provide substantial growth for safety needles.

The European region has observed a high rise in the proportion of the geriatric population and a significant increase in chronic, especially cardiovascular disease, which is projected to create the demand for safe syringes for diagnosis, treatment, and medicine intake.

Market Drivers:

  • Rising healthcare expenditure and instances of diseases are expected to increase the market.

One of the prime reasons driving the market growth of safety needles is rising healthcare expenditure and instances of diseases. With growing complexities in lifestyle, a surge in cases of cardiovascular diseases has increased. Diagnosis, treatment, and medicine intake have increased significantly, which has raised safety needle adaption. Data from the World Health Organization (WHO) shows that in 2019, 17.9 patients lost their lives owing to cardiovascular illnesses, which accounted for 32% of deaths in the year. 6.460 million deaths among patients under 65 years of age were caused by CVDs.

Rising instances of chronic diseases have significantly increased health expenditure for better healthcare. Data from the World Bank shows that per capita health expenditure has increased globally from US$999.104 in 2015 to US$1,111.082 in 2018. Increasing health expenditure and treatment are expected to surge the market for safety needles.

Furthermore, international organizations have also taken the initiative to reduce the burden of chronic diseases through awareness programs, medication, and treatments. WHO aims to reduce the global prevalence of blood pressure issues by 25% from 2010 to 2025. WHO declared that 50% of the beneficiaries under this program will receive continuous drug therapy and other treatments to prevent CVD-linked death by 2025. Promising prevention and treatment prospects are expected to increase market opportunities.

Market Restraint:

  • Rising syringe and needle waste create an environmental threat that could hamper the market.

A major problem faced by the safety needle industry is the disposal of needles. Safety syringes are predominantly single-use syringes, and their improper disposal creates syringes and needles pollution. With the rising usage of needles and syringes, a surge in syringe pollution has been observed worldwide. In March 2021, San Francisco collected more than 13,000 syringes and needles waste, an increase of 10 times than a decade ago. Furthermore, improper disposal of needles raises the chances of spreading diseases such as HIV and hepatitis. The surging needles market is expected to increase further pollution, which degrades the environment and hence has raised concerns.

Key Developments:

  • January 2023- MTD Group received FDA clearance for its DropSafeTM SicuraTM passive safety needle for intramuscular and subcutaneous injection of vaccines and drugs. The needle is designed to eliminate needlestick injuries, providing a fully safe injection experience. The needle is protected by a transparent shield that automatically locks after injection, requiring no incremental activation step by the healthcare professional (HCP). The safety of HCPs always been a top priority for MTD Group, and the DropSafeTM SicuraTM is going to be available to pharmacy chains and other healthcare practices in the US.
  • January 2023- Milestone Scientific partnered with Sweden & Martina to distribute its STA Single Tooth Anesthesia System(R) in Spain, Portugal, and France. The agreement grants Sweden & Martina exclusive rights to market STA in these markets, replacing its current distributor in Italy. The STA system, which uses precise, digitized, and computer-controlled dosing, offers painless injections, shorter wait times, fewer complications, and reduced patient cancellations. The partnership aims to grow dentists' business and improve patient experience.
  • November 2022- Neogen Corporation introduced a new dual-detecting needle for production farmers, enhancing the effectiveness of its Ideal(R) D3(TM) detectable needles. The patent-pending D3X needles feature Neogen's metal alloy needles with stronger side walls, increasing load strength and reducing the risk of bending and breaking. They also feature a highly visible red extraction collar to prevent needles from submerging in animal skin. The new needles offer increased visibility, quick removal, and increased efficiency, ensuring food safety and preventing needles from reaching consumers.
  • March 2022- NuGen Medical Devices signed a 5-year distribution agreement with Harrington Consultants Limited and Al Mufid Pharmaceuticals for the distribution of its needle-free injection device, InsuJet(TM). The agreement cover Kuwait for at least CA$ 2,000,000, with regulatory approval from Kuwait Health Authorities. Kuwait ranks third globally for adult diabetes prevalence at 24.9%. InsuJet(TM) is the first self-administered needle-free injection system approved by Health Canada, providing safe and cost-effective drug delivery for millions of patients suffering from diabetes or other chronic illnesses.

Key Market Segments:

By Type

  • Active Safety Needles
  • Passive Safety Needles

By Route Of Administration

  • Subcutaneous
  • Intravenous
  • Others

By End Users

  • Hospitals and clinics
  • Ambulatory care centers
  • Diagnostic centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Italy
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL SAFETY NEEDLES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Active Safety Needles
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Passive Safety Needles
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL SAFETY NEEDLES MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Subcutaneous
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Intravenous
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL SAFETY NEEDLES MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Ambulatory Care Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Diagnostic centers
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL SAFETY NEEDLES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Route of Administration
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Route of Administration
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. Italy
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. France
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Route of Administration
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. UAE
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Saudi Arabia
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Route of Administration
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. BD
  • 10.2. Cardinal Health
  • 10.3. B. Braun Melsungen Ag
  • 10.4. Medline Industries, Inc.
  • 10.5. Johnson & Johnson Services, Inc.
  • 10.6. Nipro Medical Corporation
  • 10.7. Smith's Group Plc
  • 10.8. Metier Medical Limited
  • 10.9. Olympus Corporation